PPTN blocked UDP-glucose and MRS2690-induced contractile responses
Vascul Pharmacol. 2018 Apr;103-105:36-46.
HL-60 human promyelocytic leukemia cells
1 nM to 100 nM
2 hours
PPTN inhibits UDP-glucose-promoted chemotaxis of HL-60 cells
Mol Pharmacol. 2013 Jul;84(1):41-9.
RAW264.7 macrophages
10–100 μg/mL
4 hours
To evaluate the antioxidative and anti-inflammatory activities of PPTN. Results showed that PPTN significantly inhibited PMA-induced ROS generation and pro-inflammatory cytokine (e.g., IL-1β and IL-6) production in macrophages.
Adv Sci (Weinh). 2025 Feb;12(8):e2405483.
PPTN HCl 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mice
Chronic neuropathic pain model (CCI model)
Oral
10 μmol/kg
Single dose
15 and its prodrugs reversed chronic neuropathic pain
J Med Chem. 2023 Jul 13;66(13):9076-9094
Mice
Chronic constriction injury (CCI) model
Intraperitoneal injection
10 μmol/kg
Single administration, observed for 1-5 h
Evaluate the antihyperallodynic effect of compound 15 in a neuropathic pain model
J Med Chem. 2022 Feb 24;65(4):3434-3459
Mice
ΒENaC transgenic mice
Intranasal instillation
100 µM
Once daily for 12 days
PPTN reduces neutrophil lung inflammation in βENaC-Tg mice
Purinergic Signal. 2016 Dec;12(4):627-635
Sprague-Dawley rats
Nerve injury-induced neuropathic pain model
Intravenous injection
5 and 10 mg/kg
Single injection or three injections on days 1, 3, and 7
To evaluate the therapeutic effects of PPTN in neuropathic pain rats. Results showed that PPTN significantly alleviated mechanical and thermal hypersensitivity, reduced microglia and astrocyte activation in the spinal dorsal horn, and promoted nerve regeneration.
搜索
